Staphylococcus aureus Community-Acquired Pneumonia During the 2006 to 2007 Influenza Season

Kallen, Alexander J.; Brunkard, Joan; Moore, Zachary; Budge, Philip J.; Arnold, Kathryn E.; Fosheim, Gregory E.; Finelli, Lyn; Beekmann, Susan E.; Polgreen, Philip M.; Gorwitz, Rachel J.; Hageman, Jeffrey

doi:10.1016/j.annemergmed.2008.04.027

Cited by 133 publications

(123 citation statements)

References 18 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…His pneumonia was not severe and he made a full and quick recovery, although the pneumonia is severe with 51% of cases due to S. aureus reporting mortality. 17 The differences in clinical courses between reported cases of staphylococcal pneumonia and this case are apparent. These facts suggest that dengue infection has the possibility to cause staphylococcal pneumonia but it may be less severe than pneumonia associated with influenza.…”

Section: Discussionmentioning

confidence: 80%

Cavity Forming Pneumonia Due to Staphylococcus aureus Following Dengue Fever

Miyata

Yoshimura

Tachikawa

et al. 2015

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. While visiting Malaysia, a 22-year-old previously healthy Japanese man developed myalgia, headache, and fever, leading to a diagnosis of classical dengue fever. After improvement and returning to Japan after a five day hospitalization, he developed productive cough several days after defervescing from dengue. Computed tomography (CT) thorax scan showed multiple lung cavities. A sputum smear revealed leukocytes with phagocytized gram-positive cocci in clusters, and grew an isolate Staphylococcus aureus sensitive to semi-synthetic penicillin; he was treated successfully with ceftriaxone and cephalexin. This second reported case of pneumonia due to S. aureus occurring after dengue fever, was associated both with nosocomial exposure and might have been associated with dengue-associated immunosuppression. Clinicians should pay systematic attention to bacterial pneumonia following dengue fever to establish whether such a connection is causally associated.

show abstract

Section: Discussionmentioning

confidence: 80%

Cavity Forming Pneumonia Due to Staphylococcus aureus Following Dengue Fever

Miyata

Yoshimura

Tachikawa

et al. 2015

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…33 Although it appears to be a relatively uncommon cause of CAP, 34 MRSA may be an important emerging respiratory pathogen in the community, associated with severe necrotizing infection especially following recent influenza. 35 …”

Section: Etiologymentioning

confidence: 99%

Pneumonia and hospitalizations in the elderly

Cacciatore¹,

Gaudiosi²,

Mazzella

et al. 2017

Geriatr Care

View full text Add to dashboard Cite

Pneumonia in the elderly is a common and severe problem. In this review we analyze the state of the art for pneumonia in the elderly. Several aspects are discussed: i) how common is the disease; signs and symptoms in the elderly; ii) the elderly must always be hospitalized and which is the best place -Intensive Care Unit or medical ward?; iii) the role of comorbidities; iv) etiology and pathogenesis; medical treatment -when and how to start; v) antibiotic resistance; vi) antibiotics in hospital acquired and ventilator related pneumonia; vii) assisted non-invasive ventilation; viii) the treatment in the terminally ill elderly patient.

show abstract

“…In addition to being one of the most common causes of ventilator-associated pneumonia, S. aureus is increasingly recognized as an important cause of community-acquired pneumonia, affecting previously healthy adults and children (8,16). This is particularly notable in association with influenza infection, where concomitant staphylococcal pneumonia is often a lethal complication (7,8,12). Up to one-half of staphylococcal pneumonia isolates are classified as methicillin (meticillin)-resistant S. aureus (MRSA), confounding the delivery of appropriate treatment and resulting in reported mortality as high as 56% (1,17,24).…”

mentioning

confidence: 99%

Anti-Alpha-Hemolysin Monoclonal Antibodies Mediate Protection againstStaphylococcus aureusPneumonia

Ragle¹,

2009

View full text Add to dashboard Cite

Staphylococcus aureus pneumonia is one of the most common invasive diseases caused by this human pathogen. S. aureus alpha-hemolysin, a pore-forming cytotoxin, is an essential virulence factor in the pathogenesis of pneumonia. Vaccine-based targeting of this toxin provides protection against lethal staphylococcal pneumonia in a murine model system, suggesting that a monoclonal antibody-based therapy may likewise prove to be efficacious for prevention and treatment of this disease. We report the generation of two distinct anti-alpha-hemolysin monoclonal antibodies that antagonize toxin activity, preventing human lung cell injury in vitro and protecting experimental animals against lethal S. aureus pneumonia. Each of these two monoclonal antibodies recognized an epitope within the first 50 amino acid residues of the mature toxin and blocked the formation of a stable alpha-hemolysin oligomer on the target cell surface. Active immunization with the first 50 amino acids of the toxin also conferred protection against S. aureus pneumonia. Together, these data reveal passive and active immunization strategies for prevention or therapy of staphylococcal pneumonia and highlight the potential role that a critical epitope may play in defining human susceptibility to this deadly disease.

show abstract

Staphylococcus aureus Community-Acquired Pneumonia During the 2006 to 2007 Influenza Season

Cited by 133 publications

References 18 publications

Cavity Forming Pneumonia Due to Staphylococcus aureus Following Dengue Fever

Cavity Forming Pneumonia Due to Staphylococcus aureus Following Dengue Fever

Pneumonia and hospitalizations in the elderly

Anti-Alpha-Hemolysin Monoclonal Antibodies Mediate Protection againstStaphylococcus aureusPneumonia

Contact Info

Product

Resources

About